GLP-1: physiological effects and potential therapeutic applications.
about
The effect of H. pylori eradication on meal-associated changes in plasma ghrelin and leptinChemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapiesIncretin-modulated beta cell energetics in intact islets of Langerhans.Early exposure of the pregestational intrauterine and postnatal growth-restricted female offspring to a peroxisome proliferator-activated receptor-{gamma} agonist.Purification of family B G protein-coupled receptors using nanodiscs: Application to human glucagon-like peptide-1 receptorThe role of adjunctive exenatide therapy in pediatric type 1 diabetes.Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primatesDifferentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.Foxa1 and Foxa2 control the differentiation of goblet and enteroendocrine L- and D-cells in miceIncretin therapy--present and future.Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans.Glucagon like peptide-1 receptor expression in the human thyroid glandEfficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial).18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.Effects of indigestible carbohydrates in barley on glucose metabolism, appetite and voluntary food intake over 16 h in healthy adults.GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgeryIn vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis.Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.Liraglutide in the management of type 2 diabetes.Novel GLP-1 receptor agonists for diabetes.The effects of food components on hormonal signalling in gastrointestinal enteroendocrine cells.The clinical potential of low-level C-peptide secretion.A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice.Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities.Effect of gelatinisation of starch with casein proteins on incretin hormones and glucose transporters in vitro.Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats.β-cell preservation and regeneration for diabetes treatment: where are we now?Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis.Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials.GLP-1 Treatment Improves Diabetic Retinopathy by Alleviating Autophagy through GLP-1R-ERK1/2-HDAC6 Signaling Pathway.Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes.Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind studyGLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction
P2860
Q21261893-0C98E1C1-3C18-49EB-883E-9AFC9AE8DA45Q33624771-48EEFA04-F2FB-43B5-8B2D-63C22AE599ADQ33701369-F4784576-3C96-4BB8-837E-1B197A0022B9Q33727430-E7C17EB1-12C1-40A1-B1FB-A094E2402BB2Q33793135-3BA18430-C46A-4C10-9A2F-DECB3B72BE3DQ33873117-4AA9AECB-F44C-47D0-B035-FF720C781546Q34150227-B7CEACE5-2F23-4DEE-B0CA-5C87BC035847Q34659509-F10F76B7-32CB-489D-A4A5-D62ABF6F8492Q35001607-6006EE5E-C686-469D-BC69-27BDD1F6CD82Q35760283-0A9D24BC-AB9A-433A-A11B-055638BDE5B7Q35886138-FB639F4E-F468-4EB4-BD47-8D3FC391360AQ36141532-1ECA3F03-28D9-4547-A9CA-094FDD024840Q36428087-851014BA-AC74-4CD7-95CF-9247F68EDE55Q36742916-1A2B6F14-5B2F-436B-AD96-1D078F587BD0Q36805409-84961C2B-FC71-4BDE-9E10-A3201AE7EA0EQ36942165-4254EF93-2E22-45D2-A120-E47BC007B9A0Q37337681-82D8F3AA-46D8-4679-89FE-428E608FF814Q37760515-B49A03EB-C53C-45B5-9F6B-D00343F8DC7EQ37813419-F9869E08-8942-4A2E-A43A-B6CF8A249E84Q37960149-EA66DBD8-5122-414A-9E31-A87790974A52Q38036910-DF07E4E7-4C42-48A7-95ED-45ACF403BD69Q38889362-3D1FCD3D-FB97-49A9-B2DE-CE6DD772D0C4Q38961417-F24CECCC-E24D-434F-A88A-57543E501D6EQ39312100-1DA830B5-326E-4CFF-AAF6-94DB1472EF09Q39511853-1886671B-2713-4759-AF55-A17B3ED60BDCQ42207255-DBA6D2C2-A73D-4A04-B7E6-D851D7542BB1Q42535316-93D641D0-FFF4-4ED3-B08D-7FFB301B3FEAQ43108062-F6D07CDC-BAAE-4827-9C7E-AB4AA96E5B37Q46071500-BE646799-DCDD-4AF7-890B-70DB826D3D63Q46148961-49B08431-5983-4D2C-9965-104A1E4AA0E7Q51301791-83FE7D63-6775-4FDC-AA50-6AC8055A7033Q51359689-C245CBE3-6D91-40D9-AB4A-C8E37E675604Q57591345-79792041-4C84-47EC-A338-54C5901A6EEDQ58757970-2493602E-9735-4B68-8022-16D89367FD68
P2860
GLP-1: physiological effects and potential therapeutic applications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GLP-1: physiological effects and potential therapeutic applications.
@en
GLP-1: physiological effects and potential therapeutic applications.
@nl
type
label
GLP-1: physiological effects and potential therapeutic applications.
@en
GLP-1: physiological effects and potential therapeutic applications.
@nl
prefLabel
GLP-1: physiological effects and potential therapeutic applications.
@en
GLP-1: physiological effects and potential therapeutic applications.
@nl
P2860
P1476
GLP-1: physiological effects and potential therapeutic applications.
@en
P2093
Kasper Aaboe
Thure Krarup
P2860
P304
P356
10.1111/J.1463-1326.2008.00853.X
P577
2008-04-22T00:00:00Z